Results 61 to 70 of about 112,380 (305)

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Modulating NPC1L1 to Potentiate PARP Inhibitor-Induced Ferroptosis and Immune Response in Triple-Negative Breast Cancer

Pharmaceutics
Background/Objectives: Poly (ADP-ribose) polymerase (PARP) inhibitors have shown significant efficacy in treating BRCA-mutated cancers; however, a significant proportion of patients fail to respond.
Ge Li, Yuxia Yuan, Xinhua Wu, Lixian Wu
doaj   +1 more source

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells [PDF]

, 2018
Paclitaxel is a treatment option for advanced or metastatic bladder cancer after the failure of first-line cisplatin and gemcitabine, although resistance limits its clinical benefits.
Flores, M. Luz, Gasca Bellido, Jessica María, Japón Rodríguez, Miguel Ángel, Jiménez Guerrero, Rocío, Medina, Rafael, Pérez Valderrama, Begoña, Romero Portillo, Francisco, Tortolero García, María Dolores   +7 more
core   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsResearch in context

EBioMedicine, 2018
Background: PARP-1 plays a critical role in DNA damage repair and contributes to progression of cancer. To explore the role of PARP-1 in acute myeloid leukemia (AML), we analyzed the expression of PARP-1 in AML and its relation to the clinical prognosis.
Xia Li, Chenying Li, Jingrui Jin, Jinghan Wang, Jiansong Huang, Zhixin Ma, Xin Huang, Xiao He, Yile Zhou, Yu Xu, Mengxia Yu, Shujuan Huang, Xiao Yan, Fenglin Li, Jiajia Pan, Yungui Wang, Yongping Yu, Jie Jin   +17 more
doaj   +1 more source

A clinical case of repeat use of PARP inhibitors in a patient with mBRCA-associated ovarian cancer

Сибирский онкологический журнал, 2022
Backgraound. High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. The prevalence of BRCA1/2 germline mutations is the highest in HGSOC.
A. B. Villert, I. A. Kolomiets, Y. A. Fesik, A. A. Ivanova, N. V. Yunusova, О. N. Churuksaeva   +5 more
doaj   +1 more source

Thy-1 interaction with Fas in lipid rafts regulates fibroblast apoptosis and lung injury resolution. [PDF]

, 2017
Thy-1-negative lung fibroblasts are resistant to apoptosis. The mechanisms governing this process and its relevance to fibrotic remodeling remain poorly understood. By using either sorted or transfected lung fibroblasts, we found that Thy-1 expression is
Bradley, John E, Espinoza, Celia R, Finley, J Cameron, Hagood, James S, Head, Brian P, Kim, Jeeyeon, Liu, Xiaoqiu, Mah, Emma J, Patel, Hemal H, Shentu, Tzu-Pin, Taype, Carmen A, Wong, Simon S   +11 more
core   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers

Frontiers in Pharmacology, 2022
PARP inhibitors have clinically demonstrated good antitumor activity in patients with BRCA mutations. Here, we described YHP-836, a novel PARP inhibitor, YHP-836 demonstrated excellent inhibitory activity for both PARP1 and PARP2 enzymes.
Tingting Du, Zhihui Zhang, Jie Zhou, Li Sheng, Haiping Yao, Ming Ji, Bailing Xu, Xiaoguang Chen, Xiaoguang Chen   +8 more
doaj   +1 more source

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source